Clik here to view.
武田获得2019年道琼斯可持续发展世界指数认可
日本大阪 (美国商业资讯)– 武田药品工业株式会社（Takeda Pharmaceutical Company Limited，“武田”）(TOKYO:4502/NYSE:TAK)今天宣布，其已入选2019年道琼斯可持续发展世界指数，较行业整体平均得分高出两倍以上。此外，武田连续第10年入选道琼斯可持续发展亚太指数。道琼斯可持续发展指数是公司强大环境、社会和治理(ESG)绩效的独立指征。...
View ArticleClik here to view.
Celltrion Healthcare Receives CHMP Positive Opinion for Novel Subcutaneous...
INCHEON, South Korea Celltrion Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for...
View ArticleClik here to view.
NovaBay Pharmaceuticals Receives Approval for Distribution of Avenova in...
EMERYVILLE, Calif. NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that it has...
View ArticleClik here to view.
New England Journal of Medicine Publishes Results of a Phase 2 Trial...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the New England Journal of Medicine has published results of a Phase 2, randomised, 12-week,...
View ArticleClik here to view.
マシモの非侵襲的・連続的ヘモグロビン（SpHb®）が貧血の早期兆候を検知する能力と貧血が患者転帰に及ぼす影響に関する研究
スイス・ヌーシャテル （ビジネスワイヤ） — マシモ（NASDAQ: MASI）は本日、Injury誌に掲載された研究で研究者らが、股関節骨折の手術を受ける高齢患者を対象に、Masimo SpHb®による非侵襲的・連続的ヘモグロビン測定により、侵襲的・断続的な検査室ヘモグロビン測定値で評価した場合に周術期貧血の検知が遅れる可能性について検討したと発表しました1。研究者らはまた、a)...
View ArticleClik here to view.
研究调查Masimo无创连续血红蛋白(SpHb®)能否更早指示贫血以及贫血对患者转归的影响
瑞士纳沙泰尔 (美国商业资讯)–Masimo (NASDAQ: MASI)今天宣布，《损伤》(Injury)杂志发表的一项研究中，研究人员采用Masimo...
View ArticleClik here to view.
Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program...
WILMINGTON, Del. Incyte (Nasdaq:INCY) today announced that the first patient has been treated in the Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream as...
View ArticleClik here to view.
ドイツの最高裁判所がアビオメッドの特許の効力を確認
米マサチューセッツ州ダンバース （ビジネスワイヤ） — ドイツの最高裁判所である連邦裁判所は最近、2015年のソラテックによる特許異議申し立てにつき、アビオメッド（NASDAQ: ABMD）に有利な判決を下し、アビオメッドのImpellaと関連した特許の効力を確認しました。 これらの特許は、アビオメッドが2015年にデュッセルドルフ地方裁判所で、ドイツにおけるHeartMate...
View ArticleClik here to view.
First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the VARSITY study, which demonstrated the superiority of the gut-selective...
View ArticleClik here to view.
New Data Presented at World Sleep Congress Demonstrate Early Signs of...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced results of a Phase 1 clinical proof of concept study of the novel investigational...
View ArticleClik here to view.
Shionogi to Present New Data at IDWeek 2019
OSAKA, Japan & FLORHAM PARK, N.J. Shionogi & Co., Ltd. (hereafter “Shionogi”) today announced that the company will deliver 20 data presentations for Shionogi compounds, including a...
View ArticleClik here to view.
Bumrungrad International Hospital at SIIA 2019: Self-Insured Employers Adopt...
MAHWAH, N.J. & BANGKOK Coinciding with the 39th Annual SIIA National Educational Conference and Expo, Sept. 30-Oct. 2, 2019, Marriott Marquis, San Francisco, California, Bumrungrad International...
View ArticleClik here to view.
Samsung Bioepis Announces Phase 3 Results of SB8, Bevacizumab Biosimilar...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced results from the Phase 3 study evaluating the efficacy and safety of SB8, a bevacizumab biosimilar candidate, compared to reference...
View ArticleClik here to view.
Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib...
WILMINGTON, Del. Incyte (Nasdaq:INCY) announces updated results, including the final result for the primary endpoint, from its Phase 2 FIGHT-202 trial evaluating pemigatinib, a selective fibroblast...
View ArticleClik here to view.
CORRECTING and REPLACING Incyte Announces Positive Updated Results from Phase...
WILMINGTON, Del. Sixth paragraph, fourth sentence of release should read: Serous retinal detachment was observed in 4 percent of patients (Grade ≥3, 1 percent) with none of the cases resulting in...
View ArticleClik here to view.
世界睡眠大会上呈报的新数据展示了选择性食欲肽2型受体(OX2R)激动剂TAK-925治疗1型发作性睡病患者有效性的早期征象
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited,...
View ArticleClik here to view.
インサイト、白斑患者でルキソリチニブ・クリームを評価する第3相臨床試験プログラムで最初の患者が治療を受けたと発表
米デラウェア州ウィルミントン （ビジネスワイヤ） — インサイト（Nasdaq:INCY）は本日、第3相TRuE-V臨床試験プログラムで最初の患者が治療を受けたと発表しました。本プログラムは、白斑の青年・成人患者（年齢12歳以上）に対する単剤療法としてのルキソリチニブ・クリームの安全性と有効性を評価するものです。...
View ArticleClik here to view.
Seattle Genetics and Astellas Announce Results from Phase 1 Trial of...
TOKYO & BOTHELL, Wash. Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced initial results from the...
View ArticleClik here to view.
CAP Laboratory Accreditation Program Expands Inspector Training Footprint in...
TOKYO The College of American Pathologists (CAP) and CGIkk hosted laboratory accreditation inspector training for 20 pathologists from leading institutions across Japan. The September 28 training...
View ArticleClik here to view.
三叶草生物制药在研1类新药SCB-313中国恶性腹水I期临床完成首例患者给药
成都 (美国商业资讯)–三叶草生物制药，一家致力于创新及变革性生物药物研发的生物制药公司，今天宣布在中国进行的另一项SCB-313 I期临床试验完成首例患者给药。SCB-313是一种创新重组人肿瘤坏死因子相关凋亡诱导配体（TRAIL）-...
View Article